

ASX Release

23 December 2022

## Middle East Joint Venture agreement investor briefing recording

Amaero International Limited ("Amaero"), (the "Company") (ASX:3DA) is pleased to invite investors to view the recording of an investor webinar on the Company's binding joint venture (JV) agreement for additive manufacturing and powder production in the United Arab Emirates, held at 11.00am AEDT on Thursday, 22 December 2022.

In the briefing, Amaero Chairman and CEO Hank Holland provided an overview of the JV opportunity, background on the JV partner, each partner's obligations and the path forward. The formal presentation was followed by a live Q and A session.

To view the recording, please click on this link: <https://www.amaero.com.au/post/amaero-22-december-2022-investor-briefing>

*This announcement is authorised for ASX release by the board of directors of Amaero International Limited.*

For further information, please contact:

**Corporate:**

**Hank J. Holland**

*Chairman and CEO*

Amaero International Limited

[hank.holland@amaero.com.au](mailto:hank.holland@amaero.com.au)

**Investors:**

**Gabriella Hold**

*Automic Group*

+61 (0) 411 364 382

[gabriella.hold@automicgroup.com.au](mailto:gabriella.hold@automicgroup.com.au)

About Amaero International Limited:

Amaero International Limited is an Australian-based company focused on titanium and other alloy powder production utilised by the additive manufacturing industry. The Company provides applied engineering and commercialisation services in collaboration with aerospace, defence and other industries that utilise additive manufacturing.

Amaero was established with the support of Monash University in 2013 to take advantage of commercial opportunities identified by the Monash Centre for Additive Manufacturing (MCAM). Amaero is co-located with MCAM in Melbourne Australia. It operates two additional facilities, in Adelaide, South Australia, and Los Angeles, California, USA.

For further information, please visit: <https://www.amaero.com.au/>